Systematic Review of Hirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention

Diego Perez De Arenaza, Marcus D. Flather, Marcelo C. Shibata, Ameet Bakhai

Research output: Contribution to journalArticlepeer-review


Thrombin plays a key role in the pathogenesis of acute coronary syndromes because it is a potent platelet agonist and converts fibrinogen to fibrin. Hirudin is a powerful, direct, and specific antithrombin agent that can be used in many therapeutic scenarios in which heparin is routinely used. In this systemic review, we summarize evidence from randomized clinical trials evaluating the benefits and risks of recombinant hirudin for the treatment of acute coronary syndromes and patients undergoing percutaneous coronary intervention.
Original languageEnglish
Pages (from-to)156-162
Number of pages7
JournalCurrent Interventional Cardiology Reports
Issue number2
Publication statusPublished - May 2001

Cite this